Literature DB >> 15338388

Tumor necrosis factor-alpha blocking agent as a treatment for nephrotic syndrome.

David Raveh1, Ovadia Shemesh, Yaakov Jack Ashkenazi, Robert Winkler, Vivian Barak.   

Abstract

We report a 13-year-old boy with refractory nephrotic syndrome (minimal change with mesangial proliferation) who failed the standard treatment protocols. There was some temporary response to large steroid doses, but even the Mendoza protocol could not induce remission. We show suppression of the proteinuria with Infliximab (Remicade) with tapering of steroids. Serial serum levels of tumor necrosis factor (TNF)-alpha are shown and discussed. We suggest studying the TNF-alpha blocking agents as optional treatment for nephrotic syndrome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15338388     DOI: 10.1007/s00467-004-1573-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  10 in total

1.  Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome.

Authors:  E Drewe; E M McDermott; R J Powell
Journal:  N Engl J Med       Date:  2000-10-05       Impact factor: 91.245

2.  Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis.

Authors:  P Verschueren; F Lensen; E Lerut; K Claes; R De Vos; B Van Damme; R Westhovens
Journal:  Ann Rheum Dis       Date:  2003-04       Impact factor: 19.103

3.  Heparin and urokinase in situ for partial thrombosis of indwelling hemodialysis catheters.

Authors:  C Baudeau; H Fitte
Journal:  Am J Kidney Dis       Date:  1993-10       Impact factor: 8.860

4.  The tumor necrosis factor family and and correlation with disease activity and response to treatment in hairy cell leukemia.

Authors:  V Barak; B Nisman; A Polliack
Journal:  Eur J Haematol       Date:  1999-02       Impact factor: 2.997

5.  Tumor necrosis factor-alpha production from mononuclear cells in nephrotic syndrome.

Authors:  Ashraf Bakr; Mohamed Shokeir; Farha El-Chenawi; Fatma El-Husseni; Ashraf Abdel-Rahman; Rasha El-Ashry
Journal:  Pediatr Nephrol       Date:  2003-04-18       Impact factor: 3.714

6.  TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide.

Authors:  E T McCarthy; R Sharma; M Sharma; J Z Li; X L Ge; K N Dileepan; V J Savin
Journal:  J Am Soc Nephrol       Date:  1998-03       Impact factor: 10.121

7.  Use of pentoxifylline in membranous nephropathy.

Authors:  D Ducloux; C Bresson-Vautrin; J Chalopin
Journal:  Lancet       Date:  2001-05-26       Impact factor: 79.321

8.  Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease.

Authors:  F Cornillie; D Shealy; G D'Haens; K Geboes; G Van Assche; J Ceuppens; C Wagner; T Schaible; S E Plevy; S R Targan; P Rutgeerts
Journal:  Aliment Pharmacol Ther       Date:  2001-04       Impact factor: 8.171

9.  Role of tumor necrosis factor-alpha on mesangial cell MCP-1 expression and monocyte migration: mechanisms mediated by signal transduction.

Authors:  R Pai; H Ha; M A Kirschenbaum; V S Kamanna
Journal:  J Am Soc Nephrol       Date:  1996-06       Impact factor: 10.121

10.  Intravenous cyclophosphamide is the drug of choice for steroid dependent nephrotic syndrome.

Authors:  Zelal Bircan; Bulent Kara
Journal:  Pediatr Int       Date:  2003-02       Impact factor: 1.524

  10 in total
  18 in total

1.  Long-term remission of nephrotic syndrome with etanercept for concomitant juvenile idiopathic arthritis.

Authors:  Shuichi Ito; Akiko Tsutsumi; Tomonori Harada; Aya Inaba; Shuichiro Fujinaga; Koichi Kamei
Journal:  Pediatr Nephrol       Date:  2010-06-09       Impact factor: 3.714

Review 2.  New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome.

Authors:  Michael van Husen; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2011-01-13       Impact factor: 3.714

Review 3.  Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T-cells to podocytes.

Authors:  Kazunari Kaneko; Shoji Tsuji; Takahisa Kimata; Tetsuya Kitao; Sohsaku Yamanouchi; Shogo Kato
Journal:  World J Pediatr       Date:  2015-01-28       Impact factor: 2.764

4.  Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.

Authors:  Eun Young Kim; Hila Roshanravan; Stuart E Dryer
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-06-16       Impact factor: 5.187

Review 5.  Genetics of childhood steroid-sensitive nephrotic syndrome.

Authors:  Alana M Karp; Rasheed A Gbadegesin
Journal:  Pediatr Nephrol       Date:  2016-07-29       Impact factor: 3.714

6.  Correlation Between Idiopathic Nephrotic Syndrome and Atopy in Children - Short Review.

Authors:  Elena Camelia Berghea; Mihaela Balgradean; Ionela-Loredana Popa
Journal:  Maedica (Bucur)       Date:  2017-01

7.  Randomized controlled trial on immunomodulatory effects of azithromycin in children with steroid-dependent nephrotic syndrome.

Authors:  Happy Sawires; Hanan Abdelaziz; Heba Mostafa Ahmed; Osama Botrous; Michael Agban
Journal:  Pediatr Nephrol       Date:  2019-05-15       Impact factor: 3.714

8.  Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.

Authors:  Melanie S Joy; Debbie S Gipson; Leslie Powell; Jacqueline MacHardy; J Charles Jennette; Suzanne Vento; Cynthia Pan; Virginia Savin; Allison Eddy; Agnes B Fogo; Jeffrey B Kopp; Daniel Cattran; Howard Trachtman
Journal:  Am J Kidney Dis       Date:  2009-11-22       Impact factor: 8.860

Review 9.  Corticosteroid-resistant nephrotic syndrome with focal and segmental glomerulosclerosis : an update of treatment options for children.

Authors:  Jochen H H Ehrich; Lars Pape; Mario Schiffer
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 10.  Monoclonal antibodies for podocytopathies: rationale and clinical responses.

Authors:  Maddalena Marasà; Jeffrey B Kopp
Journal:  Nat Rev Nephrol       Date:  2009-06       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.